Advertisement

Topics

Latest "Mifepristone Cushing Syndrome" News Stories

22:42 EST 19th January 2017 | BioPortfolio

Here are the most relevant search results for "Mifepristone Cushing Syndrome" found in our extensive news archives from over 250 global news sources.

More Information about Mifepristone Cushing Syndrome on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Mifepristone Cushing Syndrome for you to read. Along with our medical data and news we also list Mifepristone Cushing Syndrome Clinical Trials, which are updated daily. BioPortfolio also has a large database of Mifepristone Cushing Syndrome Companies for you to search.

Showing "Mifepristone Cushing Syndrome" News Articles 1–25 of 2,000+

Extremely Relevant

Corcept Therapeutics: Cushing's Syndrome Is Just The Beginning


Relevant

Is Corcept's Cushing's Program Going to Die?

On Tuesday December 20, 2016, Corcept Therapeutics (CORT) opened at $8.47 and then quickly fell to $7.80 before ending at $8.33.  Investment Bank Janney Montgomery Scott initiated coverage on Corcept with a sell rating and $7.00 price objective. The quick fall was attributed to selling int he wake of the report.Among other things, it reportedly raised objections to the expiring protection for...

Corcept Therapeutics: How is the Cushing's Program Protected?

On Tuesday December 20, 2016, Corcept Therapeutics (CORT) opened at $8.47 and then quickly fell to $7.80 before ending at $8.33.  Investment Bank Janney Montgomery Scott initiated coverage on Corcept with a sell rating and $7.00 price objective. The quick fall was attributed to selling int he wake of the report.Among other things, it reportedly raised objections to the expiring protection for...


New Monitoring System Evaluated For Antiphospholipid Syndrome Patients

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), or often also Hughes syndrome, is an autoimmune, hypercoagulable state caused...

Corcept Therapeutics Announces Encouraging Results of Phase 1/2 Trial of Mifepristone Plus Eribulin in Triple-Negative Breast Cancer

MENLO PARK, CA -- (Marketwired) -- 12/10/16 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, psychiatric and oncologic disorders by modulating the effects of the stress hormone cortisol, released efficacy data today from its Phase 1/2 trial of mifepristone to treat patien...

Corcept Therapeutics Announces Second Quarter 2016 Financial Results and Provides Corporate Update

MENLO PARK, CA -- (Marketwired) -- 08/02/16 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today reported its financial results for the quarter e...

New explanation offered for symptoms of fragile X syndrome

Until recently, scientists thought they understood one of the underlying causes of fragile X syndrome, the most common inherited cause of intellectual disability in the United States. The syndrome, which is associated with autism, was believed to be linked primarily to overactivity in a molecular pathway in the brain.

Down syndrome and the complexity of genome dosage imbalance

In this article, the author reviews the current understanding of the genetic basis for Down syndrome phenotypes, including congenital heart defects, Alzheimer disease and leukaemia. The potential for Down syndrome therapies is discussed in light of recent progress in the field.

Is Takotsubo Syndrome a Microvascular ACS?

The authors propose a new definition of Takotsubo syndrome as a microvascular form of acute coronary syndrome with similar symptoms, ECG changes, and elevated cardiac biomarkers. European Heart Journal

Medical News Today: What Home Remedies for Carpal Tunnel Syndrome Are There?

Carpal tunnel syndrome can cause numbness and pain in the hand and stems from a problem in the wrist. Find out some tips for coping with this syndrome.

Corcept Therapeutics Inc. Announces Encouraging Results Of Phase 1/2 Trial Of Mifepristone Plus Eribulin In Triple-Negative Breast Cancer

  Life Sciences Jobs   ...

Carcinoid syndrome

Dr Reichelmann speaks with ecancertv at ESMO 2016 about carcinoid syndrome, which results from carcinoid tumour invasion of organ sites and stimulation of the release of hormones. She describes the symptoms and impacts of carcinoid syndrome on patients...

VIDEO: Approach to dysfunctional lens syndrome addresses source of problem

At OSN New York 2016, Karolinne Maia Rocha, MD, discusses dysfunctional lens syndrome. In the aging eye, the first stage of dysfunctional lens syndrome is loss of accommodation. The approach to dysfunctional lens syndrome improves light scatter and aberrations, according to Rocha.

Scientists identify mutations in three genes linked to uncombable hair syndrome

Some children suffer from completely tangled hair, which cannot be combed at all. In German, the phenomenon bears the apt name "uncombable hair syndrome" or even "Struwwelpeter syndrome".

Corcept Therapeutics Q2-2016 Update

On Tuesday, August 2, 2016, Corcept Therapeutics’ (CORT) released its 21-2016 results and held a conference call.  We published Part One of a 3-part series on Corcept’s cancer program, but Corcept has a number of indications in the pot. It remains a slow train coming down the tracks, with major clinical milestones still ahead of it.

Fetal Alcohol Syndrome a Global Problem: Report

TUESDAY, Jan. 17, 2017 -- About 119,000 children worldwide are born each year with fetal alcohol syndrome (FAS), a new report finds. The syndrome refers to a group of conditions that include poor growth for the baby both in the womb and after...

Pathogenesis and management of Brugada syndrome

Brugada syndrome is a major cause of sudden cardiac death in young patients without structural heart disease. In this Review, Sieira and colleagues summarize the mechanisms involved in the development of Brugada syndrome, and discuss the available options for risk stratification and management.

Brain gene may be key to developing medications for Down syndrome

Although it’s clear that Down Syndrome is a genetic disorder caused by the occurrence of an ex

Performance of Second Generation Cortisol Assay Evaluated

Untreated disorders of the adrenocortical system, such as Cushing’s or Addison’s disease, can be fatal, and accurate quantification of a...

New Study Reveals Genetic Marker for Tourette Syndrome

The search for a genetic marker for Tourette Syndrome (TS) is starting to bear fruit, according to a report from the Tourette Syndrome Association’s International Consortium for TS Genetics...

Safer test for down’s syndrome to be offered to mothers-to-be – Daily Mail

Daily MailSafer test for down's syndrome to be offered to mothers-to-beDaily MailExpectant mothers will be offered a new, safer test for Down's syndrome, reducing the risk of miscarriage during the screening process, the Government has announced. The non-invasive prenatal test (known as NIPT) will mean far fewer women will need ...NHS to offer safer Down's syndrome test to pregnant womenThe Guardi...

Researchers identify metabolite disturbances in patients with chronic fatigue syndrome

Recently published results indicated chronic fatigue syndrome is a conserved, hypometabolic response to environmental stress, with 25% of the metabolite disturbances identified in patients were needed for the diagnosis of the syndrome.Researchers targeted 612 metabolites from 63 biochemical pathways in blood plasma for 45 patients with chronic fatigue syndrome (CFS) who were age- and sex-matched w...

Who's at Risk for Cushing's? (CME/CE)

(MedPage Today) -- New study developed formula for identifying at-risk individuals

GW Announces New Epidiolex® (CBD) Positive Phase 3 Data in Dravet Syndrome and Lennox-Gastaut Syndrome

- Posters Presented at American Epilepsy Society Annual Meeting -- New data includes key secondary efficacy endpoints - LONDON, Dec. 05, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announce...

Link between surgery and Guillain-Barré syndrome discovered

Having surgery may be linked to developing Guillain-Barré syndrome (GBS) for people with cancer or autoimmune disorders, new research suggests. The study showed that 15 percent of those who developed the syndrome had a surgical procedure within two months prior to developing the disease.


Quick Search
Advertisement
 

News Quicklinks